Home » Archives by category » Pharma Industry News
Bayer to acquire KaNDy Therapeutics to add menopause drug candidate

Bayer to acquire KaNDy Therapeutics to add menopause drug candidate

Bayer has agreed to acquire KaNDy Therapeutics, a UK clinical-stage biotech company, in a deal worth up to $900 million, in a move to grow its drug development pipeline in women’s healthcare. Through the acquisition, the German healthcare company gains access to NT-814, a non-hormonal, once-daily, oral neurokinin-1,3 receptor antagonist in developmen for the treatment […]

Ligand Pharmaceuticals to acquire protein therapeutics developer Pfenex

US biopharma company Ligand Pharmaceuticals has signed a deal worth up to $516 million to acquire Pfenex, a development and licensing biotechnology company engaged in the development of protein therapeutics, which are used in various commercial and development-stage biopharma drug candidates. As per the terms of the deal, Ligand Pharmaceuticals is offering to acquire the […]

Continue reading …
Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan

US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former’s COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is said to be a stable, prefusion protein produced by using the recombinant protein nanoparticle technology of Novavax. The coronavirus vaccine candidate also contains the company’s Matrix‑M adjuvant. Takeda […]

Continue reading …
Janssen Covid-19 vaccine candidate Ad26.COV2.S bags $1bn deal from US govt

Johnson & Johnson (J&J) said that its subsidiary Janssen Pharmaceutical has agreed to manufacture and supply 100 million doses of its SARS-CoV-2 investigational vaccine Ad26.COV2.S to the US government, in a deal worth more than $1 billion. The Janssen Covid-19 vaccine candidate will be supplied either after approval by the US Food and Drug Administration […]

Continue reading …
Bayer completes sale of animal health business to Elanco

Bayer has wrapped up its previously announced $7.6 billion sale of its animal health business division to US-based Elanco Animal Health. The transaction, which was announced in August 2019, was closed after meeting the closing conditions, which includes regulatory approvals. Following the closing of the deal, Bayer has been paid $5.17 billion in cash after […]

Continue reading …
Sanofi, GSK to supply 60 million doses of COVID-19 vaccine to UK

Pharma majors Sanofi and GlaxoSmithKline (GSK) have reached an agreement with the UK government for supplying up to 60 million doses of their jointly developed COVID-19 vaccine candidate. The agreement will be subject to a final contract issued by the British government. The COVID-19 vaccine candidate has been developed by Sanofi in partnership with British […]

Continue reading …
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer’s Disease drug candidate (AD drug candidate) UCB0107 with Roche and its subsidiary Genentech. UCB0107 is a monoclonal antibody drug candidate, which is being developed by UCB as a potential therapy for patients with progressive supranuclear palsy […]

Continue reading …
PCI Pharma Services to open new clinical center of excellence in Berlin

PCI Pharma Services, a drug development solutions provider, is set to expand its global clinical trial services with a new clinical center of excellence (COE) at its Berlin location in Germany. The pharma and biopharma outsourcing solutions provider said that the new center will enable it to grow its clinical supply-chain network into continental Europe […]

Continue reading …
AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062

AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter’s DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), which is being developed for the treatment of multiple tumor types. Daiichi Sankyo is developing the antibody drug conjugate for multiple tumors […]

Continue reading …
Curi Bio acquires Dana Solutions to boost drug discovery platforms

Curi Bio, a developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a provider of artificial intelligence and machine learning technologies for in vitro cell-based assays. Financial terms of the deal were not disclosed by the parties. Curi Bio, through the acquisition, will get access to Dana Solutions’ artificial intelligence and machine […]

Continue reading …
Page 1 of 29123Next ›Last »